Pegfilgrastim is
indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in people with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia; and to increase survival in people acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of acute radiation syndrome).[16][26][27]
See also
Lipegfilgrastim (Lonquex) – another pegylated filgrastim biosimilar with even longer half-life
^Ho, Rodney J. Y.; Gibaldi, Milo, eds. (2004).
"Pegfilgrastim". Biotechnology and Biopharmaceuticals: Transforming Proteins and Genes into Drugs. John Wiley & Sons. pp. 157–159.
ISBN978-0-471-45027-6.
Archived from the original on 20 October 2021. Retrieved 10 November 2020.
^World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization.
hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
^Parker SD, King N, Jacobs TF (November 2020).
"Pegfilgrastim". StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.
PMID30422488.
Archived from the original on 20 October 2021. Retrieved 5 November 2020.
Pegfilgrastim is
indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in people with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia; and to increase survival in people acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of acute radiation syndrome).[16][26][27]
See also
Lipegfilgrastim (Lonquex) – another pegylated filgrastim biosimilar with even longer half-life
^Ho, Rodney J. Y.; Gibaldi, Milo, eds. (2004).
"Pegfilgrastim". Biotechnology and Biopharmaceuticals: Transforming Proteins and Genes into Drugs. John Wiley & Sons. pp. 157–159.
ISBN978-0-471-45027-6.
Archived from the original on 20 October 2021. Retrieved 10 November 2020.
^World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization.
hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
^Parker SD, King N, Jacobs TF (November 2020).
"Pegfilgrastim". StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.
PMID30422488.
Archived from the original on 20 October 2021. Retrieved 5 November 2020.